Loading
An oral drug blocking the enzymes EZH2 and EZH1 produced responses in 48 per cent of people with relapsed adult T-cell leukaemia/lymphoma, most of whom had already had mogamulizumab.
A multicentre phase 2 trial of valemetostat, an EZH2 and EZH1 inhibitor, 200 mg a day by mouth until progression or unacceptable toxicity, in relapsed or refractory aggressive adult T-cell leukaemia/lymphoma (acute, lymphoma and unfavourable chronic types). The primary endpoint was overall response assessed centrally by an independent efficacy assessment committee.
Activity after mogamulizumab, in a disease with few options at that point. Single-arm and small.
Shares EZH1 and EZH2 inhibitor DS-3201b in relapsed adult T-cell leukaemia/lymphoma, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares EZH1 and EZH2 inhibitor DS-3201b in relapsed adult T-cell leukaemia/lymphoma, Adult T-cell leukaemia/lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/